Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus SOX versus SOX for perioperative locally advanced gastroesophageal junction adenocarcinoma
ChiCTR2400083556Phase 4Not yet recruiting
- Sponsor
- Linyi People's Hospital
- Start
- Apr 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fruquintinib, tegafur and oxaliplatin in gastroesophageal junction adenocarcinoma (2 arms), sponsored by Linyi People's Hospital. Primary endpoint: pathologic complete response. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
fruquintinibtegafuroxaliplatin
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400083556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083556.